Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided:

##STR00001##

or a pharmaceutically acceptable salt thereof, wherein L.sub.1, L.sub.2, L.sub.3, L.sub.4, L.sub.5, L.sub.6, L.sub.7, L.sub.8, L.sub.9, L.sub.10, Y.sub.1, Y.sub.2, Y.sub.3, Y.sub.4, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided.

The present invention relates to novel glycomimetic compounds that are rationally designed to inhibit the binding of various pathogens to cell surface sialylated galactose and methods of use thereof. Specifically sialic acid glycosides and C-glycosides are disclosed that form a lactam ring structure or a cyclic ether/amine ring structure with the adjacent monosaccharide residue.

The present invention relates to novel glycomimetic compounds that are rationally designed to inhibit the binding of various pathogens to cell surface sialylated galactose and methods of use thereof. Specifically sialic acid glycosides and C-glycosides are disclosed that form a lactam ring structure or a cyclic ether/amine ring structure with the adjacent monosaccharide residue.

The present application provides, in some aspects, methods of treating cancers, such as homologous recombination (HR)-deficient cancers. In some embodiments, the disclosure provides a method for treating cancer by administering to a subject a compound of Formula (I):(I), or a pharmaceutically acceptable salt thereof. ##STR00001##

The present application provides, in some aspects, methods of treating cancers, such as homologous recombination (HR)-deficient cancers. In some embodiments, the disclosure provides a method for treating cancer by administering to a subject a compound of Formula (I):(I), or a pharmaceutically acceptable salt thereof. ##STR00001##

The present invention encompasses compounds and methods for treating urinary tract infections.

Disclosed are compounds which can act as a positive allosteric modulator for erythropoietin and erythropoietin receptor and have the activity in promoting erythropoiesis. Also disclosed are pharmaceutical compositions comprising said compounds and treatment methods utilizing said compounds.

A modified cellulose is provided. The modified cellulose is represented by the chemical formula (1): ##STR00001##
wherein n is between 60 and 2500, at least one R is selected from one of the group consisting of ##STR00002##
R1 is C.sub.11 to C.sub.32 alkyl group or C.sub.11 to C.sub.32 alkenyl group, R2 is hydrogen, C.sub.3 to C.sub.29 alkyl group or C.sub.3 to C.sub.29 alkenyl group, R3 is C.sub.3 to C.sub.29 alkyl group or C.sub.3 to C.sub.29 alkenyl group, R4 is C.sub.4 to C.sub.8 cycloalkyl group or C.sub.4 to C.sub.8 cycloalkenyl group, n.sub.2 is between 15 and 33, n.sub.4 is between 20 and 40.

The invention provides novel compounds and conjugates of these compounds useful for the delivery of biologically active substances. Further novel design criteria for chemically stabilized siRNA particular useful when covalently attached to a delivery polymer to achieve in vivo mRNA knock down are disclosed therein.

Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active agent (for example, a drug, a toxin, a ligand, a probe for detection, etc.) having a specific function or activity, a SO.sub.2 functional group which is capable of selectively releasing the active agent, and a functional group which triggers a chemical reaction, a physicochemical reaction and/or a biological reaction by external stimulation, and may further include a ligand (for example, oligopeptide, polypeptide, antibody, etc.) having binding specificity for a desired target receptor.